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1. ABSTRACT 
 
Members of the protein 4.1 family of adapter proteins are expressed in a broad panel of tissues including various 
epithelia where they likely play an important role in maintenance of cell architecture and polarity and in control of cell 
proliferation. We have recently characterized the structure and distribution of three members of the protein 4.1 family, 4.1B, 4.1R 
and 4.1N, in mouse kidney. We describe here binding partners for renal 4.1 proteins, identified through the screening of a rat 
kidney yeast two-hybrid system cDNA library. The identification of putative protein 4.1-based complexes enables us to envision 
potential functions for 4.1 proteins in kidney: organization of signaling complexes, response to osmotic stress, protein trafficking, 
and control of cell proliferation. We discuss the relevance of these protein 4.1-based interactions in kidney physio-pathology in 
the context of their previously identified functions in other cells and tissues. Specifically, we will focus on renal 4.1 protein 
interactions with beta amyloid precursor protein (beta-APP), 14-3-3 proteins, and the cell swelling-activated chloride channel 
pICln. We also discuss the functional relevance of another member of the protein 4.1 superfamily, ezrin, in kidney physio-
pathology.   
 
2. INTRODUCTION 
 
The cytoskeleton is composed of a complex network of proteins that participates in maintenance of cell architecture 
and polarity through proper sorting and retention of transmembrane proteins. Thus, cytoskeletal proteins 4.1 and ezrin act as 
scaffold proteins by bridging an increasing list of transmembrane proteins to actin filaments and specialized adapter and signaling 
molecules (1-9).  These cytoskeleton-based interactions are dynamic and subject to regulation depending on cell activation and 
cell environment. The key role of protein 4.1 in membrane architecture and function is illustrated by the observation that a 
dramatic decrease or loss in protein 4.1 expression results in a concomitant decrease in the level of expression and 
mislocalization of transmembrane and membrane-associated proteins that normally interact with protein 4.1 (10-27). Members of 
the protein 4.1 superfamily have been originally thought to play exclusively a structural role. There is now strong evidence for 
their involvement in other cellular functions, including cell polarity (3, 15, 28-31), nuclear architecture and cell division (32-45), 
control of cell volume in response to osmotic stress (46), and control of cell proliferation (47-53). As detailed later in this review, 
the complex gene organization of the four members of the protein 4.1 family likely plays a major role in tissue and cellular 
specialization of 4.1 proteins. 
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In this review, we present evidence for potential interactions of the three major kidney protein 4.1 gene products with 
selected binding partners in an attempt to delineate the functions that these cytoskeletal proteins may play in kidney and in other 
epithelia. The potential functional relevance of protein 4.1 interactions with beta amyloid precursor protein (beta-APP), members 
of the 14-3-3 family of proteins, and the cell-swelling activated chloride channel pICln, will be explored. The involvement of 
another member of the protein 4.1 superfamily, ezrin, in kidney structure, function and pathology is also discussed in detail. 
Renal ankyrins will be evoked briefly since they are described in another chapter of this issue (see Mohler and Bennett).  
 
3. PROTEIN 4.1 STRUCTURE  
 
Protein 4.1 belongs to the Ezrin/Radixin/Moesin (ERM) superfamily of adapter proteins that bridge membrane proteins 
and actin filaments (4, 54). Members of the ERM family share a homologous region, referred to as the FERM 
(Four.1/Ezrin/Radixin/Moesin) domain (55), suggesting that they may associate with identical or related membrane proteins. The 
family of 4.1 proteins is composed of prototypical red blood cell 4.1R (56-59), and three homologs, 4.1G (60, 61), 4.1N (62-65) 
and 4.1B (66-69). Protein 4.1 genes differ in their expression pattern: 4.1R is predominantly expressed in hematopoietic tissues, 
and in regions of brain and kidney (66, 70, 71); 4.1G shows a broad distribution (60, 61, 70) but, unlike the three other 4.1 
proteins, it is not expressed in kidney (71, 72); 4.1N is mostly neuron- and kidney- specific with low expression in the retina and 
gastro-intestinal epithelium (62, 71); and 4.1B is present in regions of brain, thymus, liver, gastro-intestinal tract, pancreas, 
kidney, and testis (53, 66, 71-75). The four protein 4.1 genes have been mapped on both man and mouse chromosomes (66, 69). 
They share a similar organization characterized by the existence of multiple initiation sites combined with a large number of 
alternative exons. This results in the generation of a broad repertoire of isoforms from each protein 4.1 gene (30, 34, 58, 59, 71, 
76-93). 
 
Well-defined structural domains have been delineated within the protein 4.1 coding region (Figure 1) (94). As 
illustrated in Figure 2, the 30kD FERM domain, also referred to as MBD domain, mediates interaction of 4.1R and/or its 
homologs with numerous binding partners including various transmembrane proteins such as the anion exchanger AE1 (or band 
3) (95-97), glycophorin C (25, 98-105), CD44 (23), nectin (106) and Neurexins such as Paranodin (107-110), PDZ domain-
containing proteins p55 (12, 19, 111), discs large (Dlg) protein, also referred to as synapse-associated protein 97 (SAP97) (31, 
112, 113), and CASK (29, 114), cytoskeletal protein tubulin (115, 116), a swelling-activated chloride channel (46), and signaling 
molecules including 14-3-3 proteins (50, 117) and calmodulin (111). The FERM domain also mediates interaction of 4.1R with 
phosphatidylserine (118) and, by analogy with other members of the ERM superfamily, likely with phosphatidylinositol 4,5-
bisphosphate (PIP2) (119). Importantly, several studies have established that interactions of ERM proteins with PIP2 play a key 
role in their proper membrane targeting (120, 121). The mapping of most of the interactions described above and the 
crystallization of 4.1R FERM domain (122, 123) has unveiled the complex structure of protein scaffolds organized around this 
key functional domain. A 10kD domain, which mediates 4.1R interaction with spectrin and actin, is referred to as spectrin-actin 
binding (SAB) domain (16, 124-129). Unlike 4.1R, 4.1G and 4.1B, 4.1N is unable to form a ternary complex with spectrin and 
actin due to the poor conservation of its SAB domain (130). The SAB domain harbors also a nuclear localization signal (35, 131) 
whose activity is modulated by the FERM domain and the unique region U1 (34, 35, 132-134). The 22-24kD C-terminal domain 
(CTD) interacts with various proteins including receptors (13, 14, 17, 18, 20, 26, 27), tight junction proteins (135) and the nuclear 
mitotic apparatus-associated protein NuMA (36, 42). The four protein 4.1 genes show high homology in their FERM, SAB 
(except for 4.1N), and CTD domains (Figure 1), suggesting that they may share common functions.  
 
In contrast, the unique regions U1, U2 and U3, interspersed between the conserved domains, may confer specific 
regulatory functions upon each 4.1 protein (Figure 1). The unique region U1 has been shown to modulate 4.1R nuclear 
translocation (34, 35, 134). This region also interacts with calmodulin in a calcium-dependent manner (136) and with a 
centrosomal-associated protein (38). The unique region U1 also harbors a phosphorylation site for the cyclin-dependent cdc2 
kinase (37), the level of phosphorylation of 4.1R varying during the cell cycle. No binding partners for the U2 and U3 unique 
regions have been identified so far. The unique region U2 contains a key Ser residue that is the primary substrate for protein 
kinase C (PKC)-dependent phosphorylation of 4.1R (137). Importantly, phosphorylation of this Ser residue leads to a decrease in 
4.1R interaction with transmembrane protein glycophorin C and with spectrin and actin. Given the conservation of this Ser 
residue and of the surrounding amino acids in all four 4.1 proteins (Figure 3), one may anticipate that PKC-dependent 
phosphorylation will play a key role in regulation of 4.1G, 4.1N and 4.1B function as well. Importantly, the U2 region has been 
recently shown to confer upon 4.1B its anti-proliferative properties through a still unknown mechanism (51). No function has 
been assigned to the U3 region yet. Of particular note, inclusion or exclusion of this alternative U3 region is a hallmark of 
epithelial 4.1R and 4.1N, respectively (30, 71). This intriguing feature likely reflects unique properties assigned to each of these 
protein 4.1 gene products in epithelia, including kidney. The emerging concept is that the unique regions act as modulators of 
protein 4.1 interactions mediated by the conserved domains and that tissue- and cell-specific splicing patterns in those regions 
confer upon each protein isoform unique characteristics. 
 
4. CYTOSKELETON AND KIDNEY ARCHITECTURE AND FUNCTION  
 
  The nephron is composed of a monolayer of highly polarized epithelial cells that are uniquely suited to perform specific 
transport functions. The nonrandom distribution of membrane proteins reflects the vectorial transport functions performed by 
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these cells (41-43), and the key role played by the cytoskeleton in targeting and positioning membrane proteins in these cells (7, 
138-144). Importantly, while such protein complexes exist as soluble cytoplasmic scaffolds in non-confluent cells, they are 
targeted to cell-cell contact regions of the membrane in confluent cells, namely the lateral domain in the kidney epithelium, under 
the control of cell adhesion molecules (145-150). The apical membrane of the kidney epithelium is also divided into 
microdomains in which proteins segregate, also through interactions with the cytoskeleton (151-158). Those general concepts are 
likely to be applicable to most epithelia. 
 
4.1. Renal 4.1 proteins 
We have recently established that three members of the protein 4.1 family, i.e 4.1B, 4.1R and 4.1N, are expressed in 
mouse kidney (71). We have extensively characterized the kidney-specific splicing events in each protein 4.1 gene and the 
consequences of these splicing events on the structure of kidney protein 4.1 isoforms. Thus, compared to the full length proteins 
displayed in Figure 1, kidney 4.1B and kidney 4.1R both lack the U1 region. In addition, all three proteins lack small regions at 
the boundary of the U2 region and the SAB domain. Moreover, kidney 4.1B lacks a small N-terminal peptide in the U3 region 
and kidney 4.1N lacks most of the U3 region. Lastly, kidney 4.1B bears a truncation of the very end of the C-terminal domain 
(66, 71, 88). The absence of defined domains in renal 4.1 proteins likely confers upon their structure specific features that meet 
functional requirements in the context of the kidney epithelium.  Indeed, we and others have gathered evidence for some of these 
kidney-specific splicing events either impairing or facilitating interactions of protein 4.1 isoforms with specific binding partners.  
For example, the major isoform of kidney 4.1R lacks a small peptide encoded by exon 16. Since this peptide contains a spectrin-
binding motif (93, 129, 159, 160) and a nuclear localization signal (32, 33, 131, 161), we predict that this kidney 4.1R isoform 
will interact weakly with spectrin and will show low level of nuclear localization. A smaller pool of kidney 4.1R containing this 
peptide is expected to be targeted to unique cellular compartments and/or to interact with unique binding partners. In a similar 
fashion, the absence of the exon 21-encoded peptide in kidney 4.1B is expected to impair kidney 4.1B interaction with proteins 
such as NuMA (36, 42). We are currently gathering evidence for the U1 region modulating the binding affinity of protein 4.1 
FERM domains for selected transmembrane or membrane-associated proteins (our unpublished data). We also anticipate that 
inclusion of exon 17B-encoded peptide in the major kidney 4.1R isoform and exclusion of exon 17D-encoded peptide in kidney 
4.1N (those peptides accounting for most of the U3 region in these two 4.1 proteins, respectively) may either promote or inhibit 
4.1R and 4.1N interaction with selected renal binding partners.  
 
An intriguing feature of renal 4.1 proteins is their mutually exclusive expression along the nephron: 4.1B is primarily 
expressed in the proximal convoluted tubule (PCT) and the glomerulus, while 4.1R is detected in the thick ascending limb (TAL) 
of the loop of Henle, and 4.1N in the thin limb of the loop of Henle, the distal convoluted tubule (DCT) and all regions of the 
collecting duct (71, 72). At the cellular level, all 4.1 proteins are detected in the basolateral region of the kidney epithelium. 
Given the extensive knowledge of transport functions dedicated to each segment of the nephron, these observations strongly 
suggest that each 4.1 protein is likely involved in the organization of region-specific protein scaffolds and therefore likely plays 
unique functions in kidney.  
 
Interestingly, 4.1R null mice display not only the expected hematopoietic phenotype (chronic hemolytic anemia, 
splenomegaly, spherocytosis and reticulocytosis; (162)) but also neuro-behavioral deficits, likely resulting from the lack of 4.1R 
expression in cerebellum, dentate gyrus and hippocampus (70), and a renal phenotype (our unpublished data). Indeed, 4.1R null 
mice present with a slight urine acidification and alterations in Na/K balance upon water deprivation.  More recently, we have 
reported that 4.1R null red blood cells display hyperactivity of the sodium-proton exchanger NHE1 (163), of the “Gardos 
channel” calcium-gated potassium channel (163, 164) and of a potassium-chloride co-transporter (163). Terada et al. have also 
suggested an interaction between 4.1B and the sodium bicarbonate co-transporter NBC1 in the PCT based on electron 
microscopy analysis of kidney sections showing co-localization of the two proteins (72). Taken together, these recent findings 
provide us with interesting leads as for identifying additional ion transporters interacting with 4.1 proteins in the kidney 
epithelium.  
 
4.2. Renal ezrin  
A member of the protein 4.1 superfamily, ezrin, is expressed at high levels at the apical pole of epithelia including 
kidney (158) (Figure 4). Up-regulation of ezrin expression is a hallmark of major kidney diseases such as polycystic kidney 
disease (165) and nephrogenic diabetes insipidus (166). Ezrin, in association with PDZ domain containing protein sodium-proton 
exchanger regulatory factor 2 (NHERF-2), bridges the cytoskeleton and the integral membrane protein podocalyxin in podocytes 
(167), disorganization of this link leading to a dramatic loss in glomerular foot processes (168). A NHERF-2/podocalyxin 
complex has also been recently characterized in the apical region of MDCK cells undergoing polarization (169). In a similar 
fashion, in concert with PDZ domain-containing protein NHERF-1, ezrin has been shown to regulate sodium and phosphate 
reabsorption and proton secretion at the apical pole of the proximal convoluted tubule through its interaction with the 
sodium/phosphate co-transporter Npt2 and the sodium proton exchanger NHE3, respectively (170, 171). Thus, ezrin binds to the 
cytoplasmic domain of NHE3 but recruits also adapter and signaling molecules, i.e. NHERF-1 and cyclic AMP-dependent 
protein kinase (PKA) (172-174). Recruitment of PKA in the vicinity of NHE3 represents a key event in the regulation of NHE3 
exchanger activity. Alterations in ezrin expression and PKA signaling have been observed in polycystic kidney disease (165).  
Co-staining of mouse kidney with an anti 4.1B antibody and either an anti-ezrin or an anti-NHERF-1 antibody 
illustrates the mutually exclusive expression of renal 4.1 proteins and ezrin or NHERF-1 at the basolateral and apical pole of the 
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kidney epithelium, respectively (Figure 4). This specialized epithelial organization may play an important role in coordination of 
ion transport. Indeed the level of activity of NHE3 at the apical pole of the TAL epithelium has been demonstrated to depend on 
the level of activity of NHE1 at the basolateral pole (175-177), the integrity of the cytoskeleton being required for this functional 
link to operate (178). The potential relevance of this intriguing distribution in control of cell proliferation will be discussed later 
in this chapter.  
 
4.3. Renal ankyrins 
Structure and function of renal ankyrins are discussed in another chapter of this issue. We  will only emphasize here 
that, like renal 4.1 proteins: i) renal ankyrins are expressed as products of distinct ankyrin genes at the basolateral pole of the 
kidney epithelium; ii) these ankyrin gene products actually correspond to various isoforms generated by tissue-specific pre-
mRNA splicing events; iii) renal ankyrins show mutually exclusive expression along the nephron; and iv) renal ankyrins mediate 
proper anchorage of key ion transporters and cell adhesion molecules in the basolateral plasma membrane of the kidney 
epithelium. 
 
5. POTENTIAL FUNCTIONS FOR RENAL 4.1 PROTEINS  
 
As a first step to decipher the roles of 4.1 proteins in kidney structure and function, we have begun to identify potential 
binding partners for kidney 4.1B, kidney 4.1R and kidney 4.1N, through the screening of a rat kidney yeast two-hybrid system 
cDNA library with full length renal 4.1 proteins (71) and 4.1R CTD baits. 
 
5.1. Methodology 
A rat kidney yeast two-hybrid system cDNA library, cloned into the GAL4 activation domain vector pGAD3S-2X 
(179, 180), was screened for binding partners using baits corresponding to cDNAs encoding full length coding regions of the 
major kidney-specific isoforms of mouse 4.1N, 4.1R and 4.1B (71), or the C-terminal domain of mouse 4.1R. Baits were cloned 
into the LexA DNA binding domain vector pLEX12 (179, 180) and used for yeast transformation. Yeast transformed with each 
pLEX12 bait cDNA, was selected in absence of Tryptophane, then transformed with the pGAD3S-2X rat kidney cDNA library 
conferring upon yeast growth in absence of Leucine. Yeast was grown on triple selection plates lacking Tryptophane, Leucine 
and Histidine in order to select clones in which the bait of interest and putative preys interacted with each other. Such protein-
protein interactions restore a fully active GAL4 transcription factor and drive the expression of histidine selection and β-
galactosidase reporter genes. Selected clones were further screened for prey interaction with kidney 4.1 protein baits based on 
standard X-galactose filter assay (179, 180). β -galactosidase positive clones were then characterized by DNA sequencing using a 
forward pGAD3S-2X vector specific primer. Interactions were re-confirmed in yeast co-transformed with cDNAs coding for the 
bait and the prey of interest. Further mapping of the regions in 4.1 proteins responsible for the identified interactions was 
determined after probing preys with various truncated variants of protein 4.1 FERM and CTD domains. Only relevant clones (i.e. 
with prey coding sequences in frame) are presented below. 
 
5.2. Identification of binding partners for renal 4.1 proteins  
The results of our screen to date are summarized in Table I. The predominant binding partners for kidney 4.1B (27/32 
clones) and exclusive binding partners for kidney 4.1N (17/17 clones) correspond to three members of the 14-3-3 family of 
proteins: 14-3-3theta ,  14-3-3zeta , and 14-3-3beta. In contrast, these proteins represent a minor category of binding partners for 
kidney 4.1R (3/16 clones). Another binding partner for kidney 4.1B (5/32 clones) is pICln, a cell swelling-activated chloride 
channel previously reported to interact with 4.1R (46). Additional potential binding partners for kidney 4.1R include: a putative 
phosphatase suspected to promote cell proliferation, LRP16 (6/16 clones) (181, 182); two proteins involved in trafficking, 
SEC14L1 (1/16 clones), a mammalian homolog of yeast phosphatidylinositol/phosphatidylcholine transfer protein SEC14 (183) 
and the Rab GDP-dissociation inhibitor (GDI) Rab-GDIalpha (2/16 clones), a regulatory protein for small GTP-binding Rab 
proteins that regulates vesicle-mediated cellular transport through control of Rab GDP/GTP exchange reaction and translocation 
of Rab proteins between the cytosol and cell membranes (184-190). Of particular note, a small GTPase of the Rab family has 
been recently shown to regulate postsynaptic terminal trafficking of AMPA receptors (191), a class of receptors that has been 
recently reported to interact with 4.1N and PDZ domain-containing protein SAP 97 (20). Another 4.1R binding partner identified 
is the beta-Amyloid Precursor Protein (beta-APP) (1/16 clones), a key protein in Alzheimer's disease (AD) pathogenesis (192). 
4.1R may potentially bind to a component of the protein translation machinery involved in cytoskeleton reorganization and cell 
transformation, i.e. elongation initiation factor 1alpha (2/16 clones) (193, 194). Lastly, we identified the putative tumor 
suppressor TMEM24 (195) (1/16 clones), a gene present in the 11q23.3 locus and frequently deleted in neuroblastomas, as a 
potential binding partner for 4.1R. 
 
While it will be important to confirm the various protein-protein interactions identified by other methodological 
approaches, some of them have been previously documented in the literature. As such, we will focus our discussion on the 
following three classes of binding partners: beta-APP, 14-3-3 proteins, and the cell swelling-activated chloride channel pICln. 
 
5.3. β-Amyloid Precursor Protein: a key element in progression of neuropathies and potentially epitheliopathies 
     Progressive cerebral deposition of the amyloid beta-peptide (A-beta peptide) is an early and invariant feature of 
Alzheimer's disease (196). This peptide originates from proteolytic cleavage of the very C-terminal region of the beta-amyloid 
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precursor protein (beta-APP), a widely expressed membrane-spanning glycoprotein. Normal secretion of beta-APP involves 
proteolytic cleavage, releasing the soluble extramembranous portion and retaining a 10kD C-terminal fragment in the membrane. 
Another proteolytic processing pathway involves reinternalization of mature beta-APP from the cell surface and its targeting to 
endosomes/lysosomes.  Subsequent proteolytic cleavage of mature beta-APP in the late Golgi and/or endosomal compartment 
leads to secretion of small peptides, including the 4kD A-beta  peptide, into the extracellular milieu. Mutations in beta-APP have 
been shown to promote its proteolysis, resulting in the hypersecretion of A-beta  peptide by cells, a pre-symptomatic event in AD 
pathogenesis.  
 
Accumulation of the A-beta  peptide occurs not only in the brain but also in the abluminal basement membrane of brain 
microvessels (197) and, potentially, in epithelia, such as kidney. Indeed, the Madin Darby canine kidney (MDCK) cell line has 
been used to study beta-APP sorting and processing (196-199). A Tyr residue (Tyr653) and the immediately adjacent residues 
(654-664) in the C-terminal region of beta-APP have been shown to dictate proper basolateral sorting of the protein and secretion 
of the A-beta peptide in MDCK cells. Importantly, basolateral secretion of A-beta peptide in MDCK cells is disturbed by 
alterations of intracellular pH and by the introduction of a mutation in beta-APP associated with familial Alzheimer's disease. 
However, the impact of the accumulation of the A-beta  peptide in the basement membrane of epithelia, including the kidney 
epithelium, of AD patients has not been fully evaluated.  
 
Interestingly, 4.1R has been previously reported to co-localize with neurofibrillary tangles in brain lesions of patients 
presenting with AD (200). It must be emphasized that, at the time of this discovery, none of the three protein 4.1 homologs were 
characterized and that the antibody used in this study may have possibly cross-reacted with other 4.1 homologs, since all four 4.1 
proteins are expressed in brain (66, 70). Moreover, neurofibrillary tangles have been reported to be enriched in 14-3-3zeta (201), 
one of the 14-3-3 isoform identified as a binding partner for kidney 4.1B and 4.1N in our screening (Table I). The observation 
that 4.1R null mice display some neuro-behavioral deficits (70) highlights the importance of 4.1 proteins in brain physio-
pathology. 
 
Our yeast two-hybrid screening has identified the very last nine C-terminal amino acids of beta-APP 
(Y687KFFEQMQN) as the binding motif for 4.1R. Although this motif is located downstream of the region required for proper 
sorting of beta-APP and secretion of the A-beta peptide, one may speculate that 4.1R, and/or its homologs, could facilitate beta-
APP anchorage in the basolateral membrane of various epithelia, including kidney. One may also speculate a role for 4.1R in 
basolateral secretion of the A-beta  peptide since there is now clear evidence for the presence of a cytoskeletal network, including 
protein 4.1 homologs, on the cytoplasmic face of the Golgi apparatus and intracellular vesicles (4, 60-62, 202, 203).  
 
Lastly, it is worth highlighting that beta-APP metabolism is stimulated by metabotropic glutamate receptors (204)  and 
that its processing is regulated by these receptors in hippocampal neurons (205), a region of the brain where several protein 4.1 
homologs are detected (66). Strikingly, metabotropic glutamate receptors have been recently reported to interact with 4.1G (17) 
and may potentially interact with other protein 4.1 homologs as well. Further studies are needed to determine whether protein 4.1 
plays an important role in beta-APP metabolism and cell sorting in brain as well as in epithelia, and whether alterations in protein 
4.1 expression either facilitate or impair the progression of beta-APP-related pathologies such as AD.  
 
5.4. Cell signaling: importance of 14-3-3 proteins     
As detailed earlier, several protein-protein interactions involving protein 4.1 FERM domain have now been extensively 
documented (Figure 2). The recent characterization of an interaction between 4.1B FERM domain and members of the family of 
14-3-3 proteins adds to the diversity of protein complexes organized around the FERM domain (117). Interestingly, 4.1R FERM 
domain appears to interact weakly with 14-3-3  proteins compared to 4.1B and 4.1G FERM domains. A Phe residue (Glu-Gln-Phe359-
Glu) is necessary for 4.1B FERM domain interaction with 14-3-3epsilon,  14-3-3eta  and 14-3-3gamma  (50). Alignment of the four 
4.1 protein FERM domains revealed that this Phe residue is conserved in 4.1B, 4.1G and 4.1N but not in 4.1R where it is 
replaced by a Tyr residue (Figure 2). Importantly, a Phe359->Tyr mutation in 4.1B FERM domain impairs its interaction with 14-
3-3 proteins, providing a mechanistic explanation for the weak interaction of 4.1R with 14-3-3 proteins.  
 
Our yeast two-hybrid system screening showed that 14-3-3 proteins are major binding partners for 4.1N. The 
conservation of the key Phe359 residue in 4.1N FERM domain supports further the likeliness of interactions between 4.1N and 14-
3-3 proteins in vivo. Interestingly, the repartition of 14-3-3 clones differs between kidney 4.1N and kidney 4.1B. Indeed, 14-3-
3 beta appears as the major binding partner for kidney 4.1N, while 14-3-3theta is the predominant binding partner for kidney 
4.1B (Table I). It is likely that variations in amino acids surrounding the canonical Phe359 residue account for preferential 
interactions between specific 14-3-3 and protein 4.1 isoforms. It should be noted that the subset of 14-3-3 protein isoforms (14-3-
3beta, theta and zeta) that we identified to interact with 4.1 proteins are different from those identified by Yu et al. (117) , i.e. 14-
3-3 epsilon, eta and gamma. This may reflect tissue-specific expression of subsets of 14-3-3 isoforms. The observations 
emphasized above, i.e. distinct proportion of 14-3-3 clones among binding partners for each renal 4.1 protein and distinct 
repartition of the 14-3-3 isoform species interacting with kidney 4.1N and 4.1B, illustrate the functional specialization of 4.1 
proteins despite the high level of conservation of key functional domains.  
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The defining of an interaction between 4.1B FERM domain and a member of the 14-3-3 family of proteins, 14-3-3 
epsilon (117), provides an important clue to deciphering novel mechanisms by which protein 4.1 may control cell signaling and 
cell proliferation. The 14-3-3 family of proteins consists of adapter proteins with multiple functions (206): regulation of cell cycle 
(207, 208), cell growth (209), apoptosis (210), transcription, nuclear trafficking (211), protein sorting (212, 213), signal 
transduction (214-219), cell polarity (220-223) and cytoskeletal structure (224-226). As disruption of interaction of some 14-3-3 
proteins with 4.1B FERM domain does not impair 4.1B anti-proliferative properties (50), the precise function(s) of protein 4.1 
interactions with 14-3-3 proteins still remain(s) to be defined.  
 
For example, protein 4.1-dependent recruitment of 14-3-3 proteins could participate in regulation of activities of 
transmembrane proteins such as ion channels and calcium pumps (227). A recent study has unveiled a novel role for 14-3-3 
proteins in mediating downregulation of Na,K-ATPase activity upon stimulation of kidney cells by dopamine, 14-3-3 proteins 
recruiting PI3-kinase to the site of Na,K-ATPAse endocytosis (228). The location of the 14-3-3 binding motif in 4.1 FERM 
domain suggests potential binding competition of 14-3-3 proteins with neighboring binding partners of 4.1 FERM domain, such 
as calmodulin or PDZ domain-containing proteins (12, 19, 31, 111), depending on the cell context (Figure 2). Some of these 
dynamic interactions could be either favored or inhibited upon cell activation. Indeed, cell activation leads to an increase in 
cytosolic calcium concentration and in changes in protein phosphorylation levels, both events modulating protein 4.1 interactions 
with its binding partners (1, 24, 37, 111, 137, 229-232). Finally, interactions of selected 4.1 proteins with 14-3-3 isoforms could 
participate in the organization of other protein complexes located in cellular compartments other than the plasma membrane 
(233). One of those components could be the centrosome where protein 4.1 and 14-3-3 homologs have been detected (38, 39, 42, 
45, 233, 234).  
 
5.5.. Regulation of cell volume in response to osmotic stress: role of the cell swelling-activated chloride channel pICln 
5.5.1. Mechanisms of regulation of cell volume 
Regulation of cell volume is a critical function in kidney where the epithelium environment is characterized by very 
different ionic compositions, depending on the segment of the nephron (235). Defective cell volume regulation leads to major 
nephropathies (236, 237). Changes in cell volume are accompanied by a reorganization of the actin cytoskeleton which is 
associated with membrane ion transporters, the cytoskeleton acting as both a structural network and a sensor for cell volume 
changes. Cells maintain a constant volume despite variations in concentrations of salts in their surroundings through either 
Regulatory Volume Increase (RVI), activated when cells shrink, or Regulatory Volume Decrease (RVD), activated when cells 
swell.  
 
Two types of transporters mediate RVI, the Na,K,2Cl co-transporter BSC1 and the sodium proton exchangers NHE1, 
NHE2 and NHE4 (238-240). The reorganization of the actin cytoskeleton plays an important role in NaCl entry into the cell 
through activation of these membrane channels (241-243).  In an hypotonic environment, cells undergo RVD as a result of a loss 
of K and Cl, mediated by activation of a K,Cl co-transporter (244). This ion efflux drives an outward movement of water 
molecules and subsequently a decrease in cell volume. An outward current of chloride involving also other osmolytes, known as 
Iswell, is involved in RVD as well (245). Several cell swelling-activated proteins have been proposed to account for the Iswell 
current: chloride channels C1C-2 and C1C-3, P-glycoprotein, and, importantly in the context of this review, the chloride channel 
pICln.  
 
5.5.2. Properties of the cell swelling-activated chloride channel pICln 
5.5.2.1. pICln: a versatile protein 
pICln is an ubiquitous protein essential for cell viability (246). Its over-expression results in an increase in an outward 
Cl conductance, while its down-regulation leads to a delay and decrease in RVD (247-250). pICln therefore plays a critical role in 
RVD, a function that is altered in major nephropathies. pICln has been identified in reticulocytes and in young red blood cells 
where it accumulates in the plasma membrane through an interaction with the actin cytoskeleton (251) . In platelets, pICln 
associates with the alpha2-beta3 integrin and regulates platelet function (252). In kidney, pICln is detected predominantly in the 
cytosol of all regions of the nephron (253). In addition, it is detected at the apical pole of the epithelium in the cortex, and at both 
basolateral and apical poles in the medulla (253). While it is primarily present in the cytosol of resting cells, it is targeted to and 
inserted into plasma membrane in response to cell swelling and to diuretics (253, 254). Once inserted into the membrane, pICln 
forms a channel-like structure enabling efflux of Cl and other osmolytes, and therefore RVD.  
 
The mechanism by which pICln is targeted to the membrane is still unknown (253). However, the carboxyl terminus of 
pICln has been shown to bind to 4.1R FERM domain, suggesting a potential involvement of 4.1R in regulation of cell volume 
through proper membrane anchorage of pICln (46). Moreover, pICln binds to actin (251), to a non-muscle isoform of myosin 
light chain (255), and to a mammalian homolog of yeast Skb1 (256). Importantly, Skb1 has been shown to control cell volume in 
yeast (257), through cytoskeletal rearrangement mediated by its interaction with the p21Cdc42/Rac activated protein kinase 
Shk1(258). In summary, pICln is involved in distinct cellular processes including regulation of cell volume, cell morphology, 
cytoskeleton architecture, cell cycle and RNA processing. Thus defining of the functional relevance of pICln/4.1 interaction in 
various cellular structures is an important goal of future studies. 
 
5.5.2.2. Characterization of pICln/4.1 interaction 
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Protein pICln has been previously reported to interact in vitro and in vivo with 4.1R FERM domain (46). However, the 
recent characterization of pICln distribution in rat kidney suggests that pICln may interact with other 4.1 proteins since it is 
expressed in regions of the nephron where 4.1 proteins other than 4.1R are present (71).  
 
Interestingly, we identified pICln as a binding partner for kidney 4.1B (Table 1). As shown in Figure 5, additional 
binding assays performed in yeast revealed that full length kidney 4.1R (panel A1), kidney 4.1B (panel A4), kidney 4.1N (panel 
B1), their respective FERM domains (panels A2, A5 and B2), as well as 4.1G FERM domain (panel A6) all interact strongly with 
pICln. pICln interaction with each renal 4.1 protein may be therefore functionally relevant. Moreover, serial truncations of 4.1N 
FERM domain (panels B3-B6) enabled us to narrow down the minimal region in 4.1N FERM domain required for interaction 
with pICln to a peptide encompassing amino acids 162-280. A previous study reported that a slightly larger region of 4.1R FERM 
domain encompassing amino acids 136-283 was necessary for interaction with pICln (46). This region corresponds to the C-
terminal half of the FERM domain. As proposed earlier for 14-3-3 proteins, the regulation of pICln binding to protein 4.1 FERM 
domain may also depend on the dynamic regulation of interactions of neighboring binding partners, in particular PDZ domain 
containing proteins and calmodulin (Figure 2).  
 
Validation of the novel protein 4.1-mediated protein-protein interactions described above in vivo will rely primarily on: 
i) investigation of the phenotypes resulting from protein 4.1 gene silencing in relevant kidney epithelial cells, cells down-
regulated for protein 4.1 expression being expected to display mis-localization of binding partners, impact on 14-3-3-mediated 
cell signaling, metabolism of beta-APP and cell response to osmotic stress; ii) confirmation of the phenotypes unveiled through 
this cell based-strategy in mouse knock out models for each protein 4.1 gene as they will become available to us. Deciphering 
such phenotypes will be greatly facilitated by the rapid progress in microarray-based renal systems biology (259). Such an 
approach will enable us defining signatures as for alterations in transcriptional activity and in transduction pathways in cell lines 
subjected to protein 4.1 gene silencing and in protein 4.1 null mouse kidneys. 
 
 
6. PROTEIN 4.1 AND EZRIN: KEY PLAYERS IN CONTROL OF CELL PROLIFERATION     
 
As described earlier in this review, major kidney pathologies have been linked to ezrin over-expression. To date, none 
have been related to alterations in levels of protein 4.1 expression despite the presence of several members of the protein 4.1 
family in the nephron. We anticipate that protein 4.1-related kidney diseases, resulting from protein 4.1-dependent defects in 
membrane anchorage and/or protein processing as suggested here for AD, will be characterized in the near future. Such kidney 
diseases will very likely include proliferative diseases. Indeed, anti-proliferative properties have been extensively documented for 
4.1B (51, 53), and to a lesser extent for 4.1R (48, 49) and 4.1N (260-262). Loss of heterozygosity (LOH) of 4.1B and 4.1R genes 
has been implicated in progression of subsets of ependymomas and meningiomas (48, 49). Some lung and breast carcinomas are 
also characterized by LOH and/or hypermethylation of the 4.1B gene (263). Protein 4.1B could exert its anti-proliferative effect 
through inhibition of protein arginine N-methyltransferase 3 activity (52). Importantly, 4.1B over-expression in proliferative 
neuronal cells blocks their growth (264). In a similar fashion, we have recently established that over-expression of a kidney-
specific isoform of 4.1N, in a kidney epithelial cell line that normally expresses this isoform, leads to cell arrest (260). Two 
reports have described a concomitant loss of 4.1B and E-cadherin in cell-cell contact regions upon transition from adenoma to 
carcinoma in pancreas and colon epithelia (53, 73). We therefore predict that the loss of expression of renal 4.1 proteins could 
lead to proliferative diseases affecting primarily regions of the nephron where each 4.1 protein is solely expressed, i.e. PCT upon 
loss of 4.1B expression, TAL upon loss of 4.1R expression and DCT and collecting duct upon loss of 4.1N expression.  
 
Several proteins that have been previously described as binding partners for 4.1 proteins, and other potential binding 
partners that co-distribute with 4.1 proteins in the lateral domain of epithelial cells, likely participate in the formation of elaborate 
protein complexes responsible for cell-cell adhesion and contact inhibition. They include i) cell adhesion molecules CD44, 
TSLC1 and the E-cadherin/beta-catenin/alpha-catenin complex (23, 147, 265, 266); ii) the sodium-proton exchanger NHE1 
(267); iii) PDZ-domain containing proteins dlg (SAP 97) and CASK (29, 31); and iv) cytoskeletal proteins such as spectrin elf 
(268). Alterations in activities of the small GTP-binding proteins Rac and RhoA have been proposed to initiate the 
disorganization of actin filaments observed in proliferative epithelia (269). Alterations in the actin cytoskeleton would in turn 
lead to the loss of adhesive protein complexes responsible for epithelial cell interactions through their lateral domains. It remains 
to be established whether the depolymerization of actin filaments is sufficient to induce disorganization of cell adhesion protein 
complexes or whether the loss of protein 4.1 in plasma membrane represents a key event in triggering such a disorganization.  
 
The concept that the Four.1/Ezrin/Radixin/Moesin (FERM) domain, a highly conserved peptide among members of the 
protein 4.1 superfamily, mediates regulation of cell proliferation (270), has been recently challenged. Indeed, a recent study has 
established that the unique region U2 of 4.1B is actually responsible for inhibition of cell growth, the FERM domain-dependent 
anchorage of the U2 region to the plasma membrane representing a necessary event for inhibition of cell proliferation (51). Other 
mechanisms of control of cell proliferation mediated by protein 4.1 have been proposed. Thus, 4.1N nuclear translocation, 
occurring upon rat pheochromocytoma PC12 cell differentiation induced by nerve growth factor (261), has been shown to block 
cell proliferation through interaction of 4.1N CTD with the phosphatidylinositol-3 (PI-3) kinase enhancer PIKE, this interaction 
resulting in an inhibition of PIKE (262). A similar inhibition of PI-3 kinase through interaction of the tumor suppressor merlin 
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with PIKE has been recently reported (271). It is likely that the FERM domain, the unique region U2 and the CTD domain of 4.1 
proteins fulfill complementary functions in control of cell proliferation. In contrast with the loss of protein 4.1 expression 
observed in proliferative tissues, ezrin has been shown to be rather over-expressed upon tumorigenesis (272, 273). Furthermore, 
ezrin has been proposed to facilitate cell invasiveness and consequently to play a crucial role in metastasis (274-276). Ezrin’s 
metastatic property could result from its ability to activate the PI-3 kinase/AKT survival pathway (277), Rac1- and Ras-
dependent pathways (278, 279) and the TOR/S6 kinase/4EB1 pathway (280).  
 
An intriguing observation is the dramatic change in activities of signaling molecules such as RhoA and Rac, and of 
adhesion molecules such as CD44 or NHE1, depending on the cell context, i.e. arrested vs. proliferative cells. This so-called cell 
context would actually depend in a large part on the cross-talk between the extracellular matrix and the cell (281), this cross-talk 
having a big impact on the characteristics of plasma membrane protein complexes interacting with the cytoskeleton. Indeed, the 
proliferative cellular microenvironment mimics a serum deprivation that confers increased cell motility and invasion in breast 
cancer cells by activating NHE1 (282). NHE1 activation and the subsequent invasive phenotype of metastatic human breast cells 
appears to be coordinated by a sequential RhoA/p160ROCK/p38MAPK signaling pathway gated by direct PKA-dependent 
phosphorylation and inhibition of RhoA. The authors suggest that serum deprivation dynamically remodels the cell and 
compartmentalizes the signal module described above in leading-edge pseudopodia suggesting a topographic relation of key 
signaling protein complexes to an invasion-specific cell structure. The disorganization of physiological protein 4.1-based 
cytoskeletal complexes and the resulting formation of pathological ezrin-based cytoskeletal complexes (283) could play a key 
role in cell proliferation and invasiveness, by altering irreversibly key signaling cues such as the PKA-gated 
RhoA/p160ROCK/p38MAPK signaling pathway. In support of this hypothesis, a member of the protein 4.1 superfamily, moesin, 
has been recently shown to participate in epithelial organization and regulation of cell proliferation through inhibition of Rho 
activity, thus promoting actin polymerization (284). Other pathways could be involved as well. Thus, the Drosophila protein 4.1 
homolog, coracle, has been initially discovered as a dominant suppressor of the Drosophila EGF receptor homolog (28). The 
concept that cytoskeletal proteins can have a direct impact on cell signaling has been reinforced by an elegant study establishing a 
crucial role for spectrin elf, an homolog of red cell beta-spectrin, in regulation of the Transforming Growth Factor-alpha signaling 
pathway, through proper sorting of two key transducers of this pathway, Smad3 and Smad4 (268). These findings challenge the 
paradigm that members of the protein 4.1 superfamily act primarily as structural proteins by providing increasing evidence for a 
key role of these proteins in cell signaling through proper positioning of regulatory molecules. 
 
The role of 4.1 proteins as tumor suppressors may also result from the ability of these proteins to maintain proper cell 
volume and intracellular homeostasis through the regulation of ion transporters they interact with, i.e. NHE1 and pICln. Indeed, 
there is now clear evidence that proliferative cells display an increase in cell volume and intracellular  alkalinization (285, 286) . 
The loss in protein 4.1 expression observed upon epithelial tumor progression, could lead to mis-localization and deregulation of 
key ion transporters that normally interact with protein 4.1. Thus, NHE1 could become hyperactive in absence of protein 4.1, 
resulting in an increase in NaCl reabsorption and in proton secretion, i.e. intracellular alkalinization. Such an hypothesis is 
supported by a recent observation highlighting NHE1 hyperactivity in 4.1R null red blood c lls (163). Although the functional 
relevance of an interaction between another member of the protein 4.1 superfamily, ezrin, and NHE1 has been extensively 
documented in fibroblasts, the occurrence of this interaction in normal epithelia is unlikely given the mutually exclusive 
expression of NHE1 and ezrin, at the basolateral and apical poles, respectively (165, 267). Based on protein 4.1 and NHE1 co-
distribution in the lateral domain of epithelia, on the presence of a potential juxta-membrane protein 4.1 binding motif (VKKKQ) 
in NHE1 cytoplasmic domain and on functional alterations of NHE1 in 4.1R null red blood cells (163) , we are currently 
investigating whether 4.1R and its homologs are indeed relevant binding partners for NHE1 in kidney epithelium. We speculate 
that, upon loss of cell polarity and loss of protein 4.1 expression, an interaction between NHE1 and ezrin would be favored and 
could potentially participate in tumor progression (Figure 6). Dissecting the protein complexes organized around ezrin and 
transmembrane proteins NHE1 and CD44 would likely lead to an understanding of how ezrin promotes cell motility (287). A 
major challenge will be to understand the mechanisms governing distinct cellular distribution and opposite effects on cell 
proliferation for protein 4.1 and ezrin, despite some structural and functional homology of these two cytoskeletal proteins. 
 
7. CONCLUSION 
 
Much remains to be done to define the actual involvement of cytoskeletal protein 4.1- and ezrin-based networks in 
kidney function and the mechanisms by which they fulfill these functions in various parts of the nephron. In particular, we need 
to further our understanding of the relationships between cytoskeleton-dependent positioning of key transmembrane and adapter 
proteins and cell signaling wiring and of the consequences of alterations of the cytoskeleton on those processes. The generation 
of mouse knock out models for each of the four protein 4.1 genes will be instrumental in evaluating the impact of a selective loss 
of protein 4.1 expression in vivo and in assessing the occurrence of compensatory mechanisms through up-regulation of non 
targeted 4.1 proteins and/or other members of the protein 4.1 superfamily, such as the ERM proteins.  
 
A major challenge of future investigation will be to decipher the mechanisms responsible for the highly selective 
expression of spliceforms arising from closely related cytoskeletal protein genes in specialized regions of a given tissue and to 
evaluate the physiological implications of such an elaborate sorting. Such mechanisms likely involve a well orchestrated network 
of tissue- and cell-specific transcriptional and signaling events. Their characterization will represent a breakthrough in the 
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cytoskeleton field and will without a doubt further our understanding of the functional links between tissue architecture and 
physiology. As emphasized by Mohler and Bennett in the chapter related to ankyrins, it will be crucial in that respect to choose 
appropriate cell and animal models to decipher this fascinating machinery.  
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Abbreviations: AD: Alzheimer’s disease; beta-APP: beta-amyloid precursor protein; CD44: cluster of differentiation 44; CTD: 
C-terminal domain; DCT: distal convoluted tubule; ERM: Ezrin/Radixin/Moesin; FERM: Four.1/Ezrin/Radixin/Moesin; GTP: 
guanosine tri-phosphate; His: histidine; Leu: leucine; LOH: loss of heterozygosity; MBD: membrane binding domain; MDCK: 
Madin Darby canine kidney cells; NF2: neurofibromatosis 2; NHE1: sodium-proton exchanger isoform 1; NHE3: sodium-proton 
exchanger isoform 3; NHERF: sodium-proton exchanger regulatory factor; Npt2: sodium/phosphate co-transporter type II; PCT: 
proximal convoluted tubule; PDZ: Post Synaptic Density Protein 95kD / Drosophila Disc large / Zonula Occludens-1; PI-3: 
phosphatidylinositol-3 phosphate; PIKE: phosphatidylinositol-3 kinase enhancer; PKA: cyclic AMP-dependent protein kinase; 
PKC: protein kinase C; RVD: regulatory volume decrease; RVI: regulatory volume increase; SAB: spectrin-actin binding; TAL: 
thick ascending limb; TGF-beta: Transforming Growth Factor-beta; Trp: tryptophane; TSLC1: tumor suppressor in lung cancer 
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Figure 1. Domain organization of 4.1 proteins. Alignment of 4.1 proteins reveals the presence of three conserved domains 
(FERM domain, spectrin-actin binding (SAB) domain, and C-terminal domain (CTD)) highlighted in shades of grey and of three 
unique regions (U1, U2, U3) displayed as white boxes. Numbers in boxes refer to percent of identity of a given conserved 
domain of 4.1G, 4.1N and 4.1B to the corresponding 4.1R domain. The 4.1R map shows a unique region U3 that is only 
expressed in epithelial tissues. Note that the SAB domain is not conserved in 4.1N. 
 
Figure 2. Mapping of the binding motifs for various binding partners in protein 4.1 FERM domain. We have highlighted known 
binding motifs for various binding partners in protein 4.1 FERM domain to illustrate the close proximity of these motifs and 
therefore the possibility of steric competition depending on cellular context. A Glu-Glu-Asp (EED) motif highlighted in red in 
exon 5-encoded peptide mediates interaction with anion exchanger AE1 (95). A 47 mer peptide encoded by exon 8, highlighted 
in purple, mediates 4.1 interaction with glycophorin C (24). Exon 9- and 11-encoded peptides highlighted in green mediates 4.1 
interaction with calmodulin (111). Exon 10-encoded peptide highlighted in blue mediates 4.1 interaction with tubulin (116) and 
with PDZ domain-containing proteins p55 (111) and likely dlg (SAP 97) and CASK. A large peptide encompassing exons 9-11 
(underlined in the sequence) is necessary for 4.1 interaction with pICln (46). The Tyr residue outlined in exon-11 encoded 
peptide in 4.1R corresponds to the location of the Phe responsible for 4.1B, 4.1N and 4.1G interaction with 14-3-3 proteins (50).  
The loss of this Phe residue in 4.1R explains the weak affinity of 4.1R for 14-3-3 proteins compared to the three other 4.1 
proteins.  
 
Figure 3. Conservation of the major PKC-dependent phosphorylation site in all four protein 4.1 members. Alignment of the 
amino acid sequences of the four mouse 4.1 proteins in the region subjected to PKC-dependent phosphorylation shows 
conservation of the key phosphorylatable Ser312 residue (in larger font and shown in blue) and of an upstream Arg309 residue 
(shown in red). These two residues are components of the canonical PKC phosphorylation site K/R-X-X-S/T previously 
described in glycogen synthase (288).  
 
Figure 4. Distinct distribution of protein 4.1B and ezrin or NHERF-1 in mouse kidney proximal convoluted tubules. Staining of 
paraformaldehyde-fixed mouse kidney sections was performed as previously described (71) using a goat polyclonal anti 4.1B 
antibody (66) diluted at 3microg/ml in conjunction with either a rabbit polyclonal anti-ezrin antibody (Upstate USA. Inc., 
Charlottesville, VA) or a rabbit polyclonal anti-NHERF-1 antibody kindly provided by Dr. Stephen Lambert (University of 
Massachussetts, Worcester, MA) both diluted at 4 microg/ml. Primary antibodies were detected using anti-goat IgGs coupled to 
fluorescein isothiocyanate and anti-rabbit IgGs coupled to Texas Red. As previously reported, protein 4.1B shows exclusive 
basolateral distribution in proximal convoluted tubules (71) while ezrin and NHERF-1 are both expressed at the apical pole of the 
tubules. The tubules lacking 4.1B expression but stained with anti ezrin and anti-NHERF-1 antibodies correspond to other 
regions of the nephron. 
 
Figure 5. Mapping of the region responsible for mouse renal 4.1 protein interaction with rat pICln. Yeast strain L40 was co-
transformed with cDNAs encoding full length rat pICln and various mouse 4.1 constructs. Panel A: 1: full length kidney 4.1R, 2: 
4.1R FERM domain, 3: 4.1R CTD domain, 4: full length kidney 4.1B, 5: 4.1B FERM domain, 6: 4.1G FERM domain. Panel B: 
1: full length kidney 4.1N, 2: 4.1N FERM domain, 3: 4.1N FERM domain ∆281-297, 4: 4.1N FERM domain ∆270-297, 5: 4.1N 
FERM domain aa128-280, 6: 4.1N FERM domain aa162-280, 7: 4.1N FERM domain aa183-280. Protein-protein interaction was 
monitored using a standard X-Gal filter assay. +++: very strong interaction, ++: strong interaction, -: no interaction. 
 
Figure 6. Reorganization of plasma membrane protein complexes upon epithelial cell proliferation.  In a normal polarized 
epithelial cell, CD44, and potentially NHE1, are anchored in the lateral domain through their interaction with 4.1 proteins and the 
actin cytoskeleton. PDZ domain-containing proteins, such as dlg and/or CASK, would be also recruited in such complexes 
through interactions with 4.1 proteins (left panel). Ezrin interacts with apical transmembrane proteins such as NHE3 and recruits 
PDZ domain-containing proteins such as NHERF-1. Ezrin is therefore unable to interact with CD44 and NHE1 due to the 
mutually exclusive expression of those proteins in a different cell compartment, i.e apical pole vs. basolateral pole. Upon 
tumorigenesis, protein 4.1 is lost leading to disorganization of protein complexes present in lateral cell-cell contact regions and 
loss of cell polarity. In contrast, ezrin and its binding partner NHERF-1 become overexpressed and can now associate with CD44 
and NHE1 since the localization of these proteins is no longer mutually exclusive within the plasma membrane (right panel). The 
formation of these novel interactions, in concert with alterations in cell microenvironment, would result in alterations of CD44 
and NHE1 properties (as illustrated by changes in color patterns of those proteins between the left and the right panels) and in the 
formation of protein complexes that would promote cell proliferation and cell invasiveness. We speculate that a similar 
mechanism would occur in most proliferative epithelia, and in particular in kidney. 
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Table I. Potential binding partners for renal 4.1 proteins in kidney 
 
 
Baits Preys Number of clones Site of interaction 
    
kidney 4.1B 14-3-3theta 13/32 FERM 
 14-3-3zeta 7/32 FERM 
 14-3-3beta 7/32 FERM 
 pICln 5/32 FERM 
    
kidney 4.1R LRP16 6/16 CTD 
 14-3-3beta 2/16 FERM 
 14-3-3theta 1/16 FERM 
 SEC14L1 1/16 not determined 
 Rab-GDIalpha 2/16 not determined 
 beta-Amyloid Precursor Protein 1/16 CTD 
 Elongation Initiation Factor 1alpha 2/16 CTD 
 Tumor suppressor TMEM24 1/16 not determined 
    
CTD 4.1R alphaB-crystallin 4/8 CTD 
 LRP16 2/8 CTD 
 Elongation Initiation Factor 1alpha 2/8 CTD 
    
kidney 4.1N 14-3-3beta 12/17 FERM 
 14-3-3theta 3/17 FERM 
 14-3-3zeta  2/17 FERM 
 
  
 
 
The number of clones refers to the number of clones corresponding to the prey of interest relative to the total number of relevant 
clones pulled out with the bait. A total of 8 106, 33 106 and 27 106 Trp (+) Leu (+) yeast clones were obtained for kidney 4.1B, 
kidney 4.1R and kidney 4.1N baits, respectively.  Among those, 237, 578 and 415 clones were β-galactosidase (+) Trp (+) Leu 
(+) His (+), respectively. We have screened so far 74, 100 and 65 clones, respectively. Prior to screening of the library, we 
ascertained that none of the baits was able by itself to confer upon yeast beta-galactosidase activity and growth in absence of 
tryptophane, leucine and histidine. CTD: C-terminal domain; FERM: Four 4.1/Ezrin/Radixin/Moesin. 
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